LGM Pharma, a Boca Raton, Florida-based provider of tailored API sourcing, contract analytical testing, and drug development services, announced on October 22, 2026, that it has acquired Sannova Analytical, a contract research organization based in Somerset, New Jersey.

The acquisition brings Sannova's cGMP analytical and GLP bioanalytical capabilities under the LGM Pharma umbrella, adding GLP bioanalysis, genotoxic and nitrosamine impurity testing, and extractables and leachables evaluations to the combined company's service offering.

LGM Pharma Integrates Sannova Laboratory Capabilities

The announcement was made jointly from the company's two locations, Boca Raton, Fla., and Somerset, N.J., underscoring the geographic pairing of LGM Pharma's Florida headquarters with Sannova's New Jersey laboratory operations.

Sannova's laboratory in Somerset is now featured on LGM Pharma's website under a dedicated capabilities page, where clients can view the shared capabilities of the combined organization.

What Sannova Brings to the Combined Organization

The core of the acquisition, as described by LGM Pharma, is the expansion of the company's analytical services platform. The Somerset, N.J. laboratory adds three specific testing capabilities that LGM Pharma highlighted in its announcement: GLP bioanalysis, genotoxic and nitrosamine impurity testing, and extractables and leachables evaluations.

Genotoxic and nitrosamine impurity testing has become a prominent area of focus in pharmaceutical analytical work, and nitrosamine impurity assessment in particular is a testing category that sponsors and manufacturers must address in regulated drug product programs.

Extractables and leachables evaluations, similarly, are a specialized analytical discipline concerned with identifying and quantifying compounds that may migrate into a drug product from packaging or manufacturing materials. With the acquisition, LGM Pharma's clients can now access these capabilities through the combined organization.

The GLP bioanalytical services added through Sannova complement the cGMP analytical testing that LGM Pharma already offered. LGM Pharma's existing analytical services, as listed on its website, include analytical testing, stability services, analytical testing services for compounders, and analytical testing for manufacturers.

The addition of Sannova's GLP bioanalytical work extends this portfolio into the bioanalytical side of contract research.

Continuity for Sannova Clients

A central commitment in the announcement concerns continuity for Sannova's existing client base.

According to LGM Pharma, Sannova clients will keep their team, their methods, and their contacts following the acquisition. In other words, the client relationships and the technical methods that Sannova clients have developed are preserved, and the same people at Sannova who have been serving those clients remain in place.

At the same time, those clients gain something new: access to LGM Pharma's API sourcing and regulatory intelligence.

LGM Pharma positions itself as a provider of tailored API sourcing, and its sourcing arm includes strategic sourcing, a 505(b)(2) pathway offering, regulatory support, logistics, and a manufacturer management program.

For a Sannova client, this means that the analytical testing work they already conduct at the Somerset laboratory can now be paired, if they choose, with LGM Pharma's upstream sourcing and regulatory services.

LGM Pharma's Broader Service Platform

To understand what the acquisition adds to, it helps to look at LGM Pharma's existing structure as presented on its website. The company organizes its offerings around three main pillars: API products, API sourcing, and CDMO services, alongside its analytical services division.

The API sourcing division encompasses strategic sourcing, regulatory support, logistics, and the manufacturer management program, as well as a dedicated 505(b)(2) pathway service.

The CDMO services division covers formulation development, solid dose delivery systems, liquids and suspensions, semi-solids, suppositories, commercial scale-up facilities and equipment, and regulatory management.

The analytical services division, as noted above, includes analytical testing, stability services, and testing services tailored to compounders and to manufacturers.

With Sannova now part of the organization, the analytical services division carries the added capabilities of the Somerset laboratory, and the combined company's website directs visitors to a page describing the capabilities available with Sannova Analytical.

The Somerset, N.J. Laboratory

Sannova Analytical operates as a contract research organization, and its laboratory in Somerset, New Jersey, is now identified on LGM Pharma's site as the location delivering the newly added GLP bioanalysis, genotoxic and nitrosamine impurity testing, and extractables and leachables evaluations.

The announcement's subheadlines place the emphasis directly on the Somerset laboratory as the source of the expanded capabilities, describing it as the facility that "adds GLP bioanalysis, genotoxic and nitrosamine impurity testing, and extractables and leachables evaluations."

The pairing of a Somerset laboratory with a Boca Raton headquarters gives the combined company operations on both sides of the deal's joint dateline, with the October 22, 2026 announcement issued jointly from both cities.

What the Announcement Says, and Doesn't Say

The information available about this transaction comes from LGM Pharma's own announcement and website. The company has stated what the acquisition adds, whom it affects, and what existing clients can expect. What the announcement does not include, and what this article therefore does not report, are financial terms of the deal, names of executives involved, statements about headcount, or plans for physical expansion of either facility. Those details were not part of the source material.

What is clear from the announcement is the strategic logic as LGM Pharma presents it: a company whose core business includes API sourcing, contract analytical testing, and drug development services has brought in a contract research organization whose laboratory specializes in cGMP analytical and GLP bioanalytical work, with particular strengths in genotoxic and nitrosamine impurity testing and extractables and leachables evaluations.

Existing Sannova clients continue with the same team, methods, and contacts, while gaining a doorway into LGM Pharma's API sourcing and regulatory intelligence offerings.

For clients of the combined organization, the practical effect described by the company is a widened service menu: analytical testing that can now span GLP bioanalysis and specialized impurity testing alongside the stability services, compounder testing, and manufacturer testing that LGM Pharma already provided, all connected to the sourcing and regulatory capabilities that formed the foundation of LGM Pharma's business.

The acquisition was announced October 22, 2026, and the combined capabilities are now presented on LGM Pharma's website under both its analytical services section and the dedicated Sannova capabilities page.

Track Every United States Chemical Project Before Your Competitors Do

When a new ethylene cracker breaks ground in the United States, the ripple effects reach engineering firms, equipment suppliers, logistics providers, and investors across the country. The question is simple: will you hear about it in time to act?

The Global Project Tracking (GPT) platform by Blackridge Research gives chemical sector stakeholders a structured, real-time view of capital projects across the United States, from early-stage announcements through final commissioning. Whether you're targeting feedstock expansions, specialty chemical plants, or downstream polymer facilities, the intelligence arrives early enough to shape your bid strategy.

Every project profile is enriched with timelines, ownership details, scope descriptions, and contact intelligence, so your business development team spends less time hunting and more time winning.

• Upcoming Projects

• Tender Notices

• Contract Awards

• Projects Under Construction

• Completed Projects

See how leading chemical industry players stay ahead of the project pipeline. Book a Free Demo of the Global Project Tracking (GPT) platform by Blackridge Research today.